{"name":"International Extranodal Lymphoma Study Group (IELSG)","slug":"international-extranodal-lymphoma-study-group-ielsg","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"high dose cytarabine","genericName":"high dose cytarabine","slug":"high-dose-cytarabine","indication":"Acute myeloid leukemia (AML)","status":"phase_3"},{"name":"chlorambucil (drug)","genericName":"chlorambucil (drug)","slug":"chlorambucil-drug","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_3"},{"name":"rituximab+chlorambucil","genericName":"rituximab+chlorambucil","slug":"rituximab-chlorambucil","indication":"Follicular lymphoma","status":"phase_3"}]}],"pipeline":[{"name":"high dose cytarabine","genericName":"high dose cytarabine","slug":"high-dose-cytarabine","phase":"phase_3","mechanism":"High-dose cytarabine is a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA, leading to cell death in rapidly dividing cells.","indications":["Acute myeloid leukemia (AML)","Acute lymphoblastic leukemia (ALL)","Primary CNS lymphoma","Lymphoma (as part of combination chemotherapy regimens)"],"catalyst":""},{"name":"chlorambucil (drug)","genericName":"chlorambucil (drug)","slug":"chlorambucil-drug","phase":"phase_3","mechanism":"Chlorambucil is an alkylating agent that cross-links DNA strands, preventing cell division and causing cancer cell death.","indications":["Chronic lymphocytic leukemia (CLL)","Lymphomas (Hodgkin and non-Hodgkin)","Waldenström macroglobulinemia"],"catalyst":""},{"name":"rituximab+chlorambucil","genericName":"rituximab+chlorambucil","slug":"rituximab-chlorambucil","phase":"phase_3","mechanism":"Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells, while chlorambucil is an alkylating agent that interferes with DNA replication.","indications":["Follicular lymphoma","Mantle cell lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE9aUWtKTnNRRFo1ZEVlWTdYNVl6bFpqR3djcVB5Rlg5XzJPcFlkb3ZDZ2NKUFBPb2pmVWtCVkhJNmdqb0ZNQ1lqcGVmbHZkTnNDdU02b2E0WG5rMExTNUNfd29MVDJjVzg?oc=5","date":"2024-06-04","type":"pipeline","source":"Wiley Online Library","summary":"Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up - Wiley Online Library","headline":"Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOOVFkVUJGYXpuU21RWlJKTmZNOWY4THN1NTFTVGota3R3dmFzM09HMXFvb09SdG5mUTZPRWNTT1NzeXRlckRiV3Z1ZXRJaWkxbExmY2VsSGlHdmlQNm1MOXBZbnV3ZE9LR3pIdkJmVHNHb0RYRS13dXQ2N0g5aVAwNUZaVjZDS0p4YWdDaw?oc=5","date":"2022-12-20","type":"pipeline","source":"Frontiers","summary":"Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-term survival after local radiotherapy: A case report - Frontiers","headline":"Clinical use of HD-MTX monotherapy in a rare case of refractory primary bone diffuse large B-cell lymphoma with long-ter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE95U05meWkyOTlvRkRNMzA3YkVwNU5UekhZSmpCWG1qTjZleWRPaFNhZnBhQWswUm1GSHlXSEZldkZIV08xWk1nWG1SOFJGcmhuV1FqcFBlLVNaZTE4U2lhcmNaRmRiYjNUSmc?oc=5","date":"2022-09-03","type":"pipeline","source":"Wiley Online Library","summary":"Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma - Wiley Online Library","headline":"Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNTDhRYzZhdGRueGF4Zlo4VkdsSjhVZ2hiS0cxWnFwRG04dElYMDYtTEJ5ck9rT2labUZyVVZWYXZxUFlUWjFqQ0VEdzRCSEN0RFFHWjJkblRhZEV5SEhNZlFJdWZubkM4ZkFyYWVMeTl2WktaRFpwUWprZ3V2bFU1OXVXcDh1bXNzS2tRdG13NVdqd2ZnTmxJYmVwNlpzOENfb2xiZ3VNQXFEenE4V1VRY2ROLUQ4dw?oc=5","date":"2021-01-27","type":"pipeline","source":"University of Southampton","summary":"New treatment regime can improve survival for patients with a rare blood cancer - University of Southampton","headline":"New treatment regime can improve survival for patients with a rare blood cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxPMjhxRFRJSDVSZEFvWjNkNDNTZ1JYR2oyRWR5djFMeFFVQnQxM016ckU0TnFkUGpFQjF0OVlqbm5lWkJDNUxQendHZS1EdHJJdzBZZGhMZ2RFZ1phUWswTkd0RnRQSWsxNXdPVTFZSFVjWWFyck5GSm5JSlFTNkFJQ3V2VEZaREtLV2VxRFZUcDZhcl93TURTNEd1b0xYdjA3N2xSV3AzMmJ1NFR5VmFfRHJubUtWc3hObHFZbTdrQjN1OW00M2RsV2pvMHdreW1nVWVHNVNscWQzZUxEaTFYX1FZSmZCeWhtUWRrRnB0dkxSak1KdjF3VThfZ3VPekRjTXZBaA?oc=5","date":"2017-03-30","type":"pipeline","source":"Lymphoma Hub","summary":"IELSG-19 Final Results: Is Combination Chlorambucil And Rituximab More Effective Than Monotherapy In The Treatment Of MALT Lymphoma? - Lymphoma Hub","headline":"IELSG-19 Final Results: Is Combination Chlorambucil And Rituximab More Effective Than Monotherapy In The Treatment Of MA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE1vODRYMWtFVHJlbFd0bURpbW00SHJtQ0xBQTluMUthVnQybW4zam90bFhmQ2ctX19JTGE2dWxjLWh2dHRxMVJIaWN0akVTOGNv?oc=5","date":"2010-02-02","type":"trial","source":"nature.com","summary":"Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trial | British Journal of C","headline":"Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokin","sentiment":"positive"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}